Preventive Care

  • Our evolving understanding of primary aldosteronism
    Ali Mehdi, MD, MEd, FACP, Pratibha Rao, MD, MPH and George Thomas, MD
    Cleveland Clinic Journal of Medicine April 2021, 88 (4) 221-227; DOI: https://doi.org/10.3949/ccjm.88a.20166

    Current screening and confirmatory testing lack sensitivity and carry a poor negative predictive value.

  • Vaccination in pregnancy: A call to all providers for help
    Jonathan D. Emery, MD and Daniel Moussa, BS
    Cleveland Clinic Journal of Medicine March 2021, 88 (3) 157-162; DOI: https://doi.org/10.3949/ccjm.88a.20111

    Vaccination in pregnancy is a public health priority that is often neglected.

  • Prostate cancer screening and the role of PSA: A UK perspective
    Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 14-16; DOI: https://doi.org/10.3949/ccjm.88a.20164

    We advocate PSA screening for all middle-aged men, especially if they have risk factors.

  • Prostate cancer: To screen or not to screen? The question is complicated
    Timothy Gilligan, MD
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 17-18; DOI: https://doi.org/10.3949/ccjm.88a.20192

    Prostate cancer screening is controversial due to the complexity of harms and benefits.

  • The role of SGLT-2 inhibitors in managing type 2 diabetes
    Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

    These drugs improve glycemic control and offer cardiovascular and metabolic benefits.

  • SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
    Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190

    Randomized controlled trials of these new agents had positive outcomes.

  • In Reply: COVID-19 coagulopathy
    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/cjm.87c.12002

    An attempt to balance the potential risks and benefits of intensified prophylaxis.

  • COVID-19 coagulopathy
    Anup Katyal, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/ccjm.87c.12001

    Skepticism of high-intensity prophylaxis for patients with D-dimer ≥ 3.0 µg/mL.

  • Assessing stable coronary artery disease
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 713; DOI: https://doi.org/10.3949/ccjm.87c.12003

    Differences between the coronary calcium score and CT coronary angiography

  • In Reply: Assessing stable coronaryartery disease
    Vinayak Nagaraja, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 714; DOI: https://doi.org/10.3949/ccjm.87c.12004

    CT angiography is the appropriate test to exclude left main disease.

Pages